GRI Bio, Inc. (NasdaqCM: GRI)
Health Care · Biotechnology · US
$1.94
+16.17% today · -95.9% 1Y
GRI Bio, Inc. (NasdaqCM: GRI) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.96M and employs 4 people.
Over the last twelve months the share price has lost 95.9%, trading between 1.36 and 80.36.
Tweenvest scores GRI Bio, Inc. across four factors: quality 26/100. Its strongest factor is quality.
GRI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.96M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -11.56
- Dividend yield
- —
- Beta (5Y)
- -0.66
- 52-week high
- $80.36
- 52-week low
- $1.36
- Avg volume (3M)
- —
- Shares outstanding
- 1.77M
- Employees
- 4
- Next earnings
- —
About GRI Bio, Inc.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
- ISIN
- US3622AW5029
- Founded
- 2009
- Listed since
- Feb 10, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $261.61 | -1.57% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.27 | +0.01% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.80 | +0.02% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $550.52 | -0.42% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $823.79 | -1.17% |
| argenx SEENXTBR: ARGX | $64.17B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $146.35 | -7.86% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.